Top

Published in:

Open Access 01-12-2019 | Breast Cancer | Commentary

PIK3CA-CDKN2A clonal evolution in metastatic breast cancer and multiple points cell-free DNA analysis

Authors: Maria Palmieri, Margherita Baldassarri, Francesca Fava, Alessandra Fabbiani, Giuseppe Maria Campennì, Maria Antonietta Mencarelli, Rossella Tita, Stefania Marsili, Alessandra Renieri, Elisa Frullanti

Published in: Cancer Cell International | Issue 1/2019

Abstract

Background

Daily experience tells us that breast cancer can be controlled using standard protocols up to the advent of a relapse. Now new frontiers in precision medicine like liquid biopsy of cell free DNA (cfDNA) give us the possibility to understand cancer evolution and pick up the key mutation on specific cancer driver gene. However, tight schedule of standardized protocol may impair the use of personalized experimental drugs in a timely therapeutic window.

Main body

Here, using a combination of deep next generation sequencing and cfDNA liquid biopsy, we demonstrated that it is possible to monitor cancer relapse over time. We showed for the first time the exact correspondence from the increasing clonal expansion and clinical worsening of metastatic breast cancer.

Conclusion

Thanks to liquid biopsy may be possible to introduce new experimental drugs in the correct therapeutic window which would lead in the near future to an effective treatment which otherwise remains challenging.

Melchardt T, Magnes T, Hufnagl C, Thorner AR, Ducar M, Neureiter D, et al. Clonal evolution and heterogeneity in metastatic head and neck cancer-an analysis of the Austrian Study Group of Medical Tumour Therapy study group. Eur J Cancer. 2018. https://doi.org/10.1016/j.ejca.2018.01.064.CrossRefPubMed

Fouillet L, Daguenet E, Schein F, Tavernier E, Flandrin-Gresta P, Cornillon J. Clonal evolution of myelofibrosis treated with hematopoietic transplantation, using RUXOLITINIB for chronic GvHD: a case report. Curr Res Transl Med. 2018. https://doi.org/10.1016/j.retram.2018.07.001.CrossRefPubMed

Pinto AM, Papa FT, Frullanti E, Meloni I, Tita R, Caselli R, et al. Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia. Br J Haematol. 2019. https://doi.org/10.1111/bjh.15147.CrossRefPubMed

Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Slifker M, et al. Clinical utilization pattern of liquid biopsies (LB) to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer (mCRC) patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Front Oncol. 2019. https://doi.org/10.3389/fonc.2018.00652.CrossRefPubMedPubMedCentral

Jacoby MA, Duncavage EJ, Chang GS, Miller CA, Shao J, Elliott K, et al. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight. 2018. https://doi.org/10.1172/jci.insight.98962.CrossRefPubMedPubMedCentral

Lee JH, Jeong H, Choi JW, Oh HE, Kim YS. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer. Medicine. 2018. https://doi.org/10.1097/MD.0000000000012862.CrossRefPubMedPubMedCentral

Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, Shimoda M, et al. Detection of TP53/PIK3CA mutations in cell-free plasma DNA from metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer. 2016. https://doi.org/10.1016/j.clbc.2016.05.004.CrossRefPubMed

Spinella JF, Richer C, Cassart P, Ouimet M, Healy J, Sinnett D. Mutational dynamics of early and late relapsed childhood ALL: rapid clonal expansion and long-term dormancy. Blood Advances. 2018. https://doi.org/10.1182/bloodadvances.2017011510.CrossRefPubMedPubMedCentral

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 2018. https://doi.org/10.1158/2159-8290.CD-17-0891.CrossRefPubMedPubMedCentral

10.

Gul A, Leyland-Jones B, Dey N, De P. A combination of the PI3 K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. Am J Cancer Res. 2018;8:2359–76.PubMedPubMedCentral

Title: PIK3CA-CDKN2A clonal evolution in metastatic breast cancer and multiple points cell-free DNA analysis
Authors: Maria Palmieri
Margherita Baldassarri
Francesca Fava
Alessandra Fabbiani
Giuseppe Maria Campennì
Maria Antonietta Mencarelli
Rossella Tita
Stefania Marsili
Alessandra Renieri
Elisa Frullanti
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-019-0991-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Main body

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Expression signatures and roles of microRNAs in inflammatory breast cancer

Metabolic characteristics revealing cell differentiation of nasopharyngeal carcinoma by combining NMR spectroscopy with Raman spectroscopy

The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma

Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway

Alpha-mangostin induces endoplasmic reticulum stress and autophagy which count against fatty acid synthase inhibition mediated apoptosis in human breast cancer cells

TRIM27 promotes the development of esophagus cancer via regulating PTEN/AKT signaling pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer